Psoriasis as an Immune-Mediated Inflammatory Disease
Psoriasis affects approximately 125 million people globally, causing chronic inflammatory skin plaques driven by aberrant Th17 and Th1 immune activation. Environmental triggers including chemical exposures may initiate or exacerbate psoriatic flares.
PFAS and Th17 Immune Axis
PFAS compounds promote Th17 differentiation by altering dendritic cell cytokine production. Elevated IL-17 and IL-23 levels—key psoriasis drivers—are associated with higher PFAS serum concentrations in cross-sectional studies.
Metabolic Comorbidities
Psoriasis patients frequently have metabolic comorbidities including obesity, dyslipidemia, and insulin resistance—all conditions also associated with PFAS exposure. The overlap suggests shared mechanistic pathways between PFAS toxicity and psoriasis pathogenesis.
Biologics and Environmental Context
Patients on biologic therapies for psoriasis who show suboptimal responses should be evaluated for ongoing environmental triggers including PFAS. Reducing chemical body burden may improve treatment efficacy for some individuals.